hackint0sh/temp-data huggingface dataset:
protocolSection identificationModule nctId: NCT06273111, orgStudyIdInfo id: 73840, briefTitle: Topical Simvastatin for Treating Infantile Hemangioma, acronym: TSTIH, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04-01, primaryCompletionDateStruct date: 2025-07-31, completionDateStruct date: 2025-12-31, studyFirstPostDateStruct date: 2024-02-22, lastUpdatePostDateStruct date: 2024-02-22, sponsorCollaboratorsModule leadSponsor name: Joyce Teng, class: OTHER, collaborators name: Stanford University, descriptionModule briefSummary: This is a 24-week, open-label pilot study to evaluate the safety and preliminary efficacy of 5% simvastatin ointment in treating 12 children with superficial IH.The primary objective:To evaluate the safety and tolerability of topical treatment with 5% simvastatin ointment for superficial IH over 24 weeks.The secondary objective:1.1 To evaluate the efficacy of 5% simvastatin ointment when topical treatment is administered twice daily for 24 weeks. Evaluation is performed at each clinic visit via investigator global assessment (IGA) based on standardized 3D digital photography and hemangioma activity score (HAS).1.2 To evaluate the impact of 5% simvastatin ointment on quality of life using the IH-QoL questionnaire., conditionsModule conditions: Hemangioma Skin, designModule studyType: INTERVENTIONAL, phases: EARLY_PHASE1, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 12, type: ESTIMATED, armsInterventionsModule interventions name: 5% simvastatin ointment, outcomesModule primaryOutcomes measure: Number of Participants with Treatment-Related Adverse Events, secondaryOutcomes measure: Percentage of participants achieved a 50% HAS reduction at week 12 compared to baseline, secondaryOutcomes measure: Percentage of participants achieved a 75% HAS reduction from baseline by the end of the study (week 24) compared to baseline., secondaryOutcomes measure: Percentage of targeted hemangiomas with complete or nearly complete resolution (IGA 0 or 1), defined as a minimal degree of telangiectasia, skin thickening, and no definitive palpable cutaneous texture changes., secondaryOutcomes measure: Percentage of targeted hemangiomas that are stabilized (no noticeable change to baseline) or continue to progress., secondaryOutcomes measure: Percentage of participants with a significant improvement in quality-of-life, defined as > 50% reduction in the IH-QoL questionnaire score from baseline to week 24., eligibilityModule sex: ALL, minimumAge: 3 Months, maximumAge: 5 Years, stdAges: CHILD, contactsLocationsModule locations facility: Stanford University, city: Palo Alto, state: California, zip: 94304, country: United States, contacts name: Ramrada Lekwuttikarn, MD, role: CONTACT, phone: 650-313-8207, email: ramrada1@stanford.edu, contacts name: Thomas Buschbacher, role: CONTACT, phone: 352-278-7603, email: tbusch@stanford.edu, geoPoint lat: 37.44188, lon: -122.14302, hasResults: False
protocolSection identificationModule nctId: NCT06273098, orgStudyIdInfo id: 73162, briefTitle: School-Based Bladder Health Intervention, statusModule overallStatus: WITHDRAWN, startDateStruct date: 2028-01-01, primaryCompletionDateStruct date: 2033-12-31, completionDateStruct date: 2033-12-31, studyFirstPostDateStruct date: 2024-02-22, lastUpdatePostDateStruct date: 2024-04-24, sponsorCollaboratorsModule leadSponsor name: Stanford University, class: OTHER, descriptionModule briefSummary: The aim of this study is to promote healthy bladder behaviors among school children. We hypothesize that a combination of bladder health education and awareness events, additional resources such as a water station to support healthy bladder behaviors, and tailored changes to classroom bathroom policies can promote healthy bladder behaviors among school children., conditionsModule conditions: Urinary Dysfunction, conditions: Lower Urinary Tract Symptoms, conditions: Urinary Tract Infections, conditions: Urinary Tract Infections in Children, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: HEALTH_SERVICES_RESEARCH, maskingInfo masking: NONE, enrollmentInfo count: 0, type: ACTUAL, armsInterventionsModule interventions name: Bladder Health Education, outcomesModule primaryOutcomes measure: Bathroom use, primaryOutcomes measure: Symptom score, primaryOutcomes measure: Urine volume, eligibilityModule sex: ALL, minimumAge: 5 Years, maximumAge: 10 Years, stdAges: CHILD, contactsLocationsModule locations facility: Stanford Hospital and Clinics, city: Palo Alto, state: California, zip: 94304, country: United States, geoPoint lat: 37.44188, lon: -122.14302, hasResults: False
protocolSection identificationModule nctId: NCT06273085, orgStudyIdInfo id: MOD00016877, briefTitle: Intensive Education Versus Usual Education of Patients for Improving Guideline Directed Medical Therapy (GDMT) Prescription in Heart Failure With Reduced Ejection Fraction, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-02-01, primaryCompletionDateStruct date: 2025-02, completionDateStruct date: 2025-02, studyFirstPostDateStruct date: 2024-02-22, lastUpdatePostDateStruct date: 2024-02-26, sponsorCollaboratorsModule leadSponsor name: Medstar Health Baltimore, class: OTHER, descriptionModule briefSummary: The goal of this randomized clinical trial is to test the effect of patient education on extent of use of guideline directed medical treatment (GDMT) of heart failure with reduced ejection fraction. The main question that our study aims to answer is if patient education can improve the adherence to GDMT in heart failure with reduced ejection fraction. Participants will receive educations about GDMT benefits in 1,3 and 5 months after discharge from hospital., conditionsModule conditions: Heart Failure, conditions: Patient Acceptance of Health Care, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: DOUBLE, whoMasked: INVESTIGATOR, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 500, type: ESTIMATED, armsInterventionsModule interventions name: Patient education, outcomesModule primaryOutcomes measure: Change in GDMT score, secondaryOutcomes measure: Heart Failure hospitalization, secondaryOutcomes measure: cardiovascular death/Left Ventricular Assist Device implantation/Cardiac Transplant, secondaryOutcomes measure: Number of GDMT classes of medications in use, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Medstar Union Memorial Hospital, status: RECRUITING, city: Baltimore, state: Maryland, zip: 21218, country: United States, contacts name: Ahmad Amin, MD, role: CONTACT, phone: 401-533-0696, email: ahmad.amin@medstar.net, geoPoint lat: 39.29038, lon: -76.61219, locations facility: Medstar Harbor Hospital, status: RECRUITING, city: Baltimore, state: Maryland, zip: 21225, country: United States, contacts name: Sumanth Bandaru, MBBS, role: CONTACT, phone: 646-240-5289, email: sumanthkumar.bandaru@medstar.net, geoPoint lat: 39.29038, lon: -76.61219, locations facility: Medstar Franklin Medical Center, status: RECRUITING, city: Baltimore, state: Maryland, zip: 21237, country: United States, contacts name: Anup Agarwal, MD, role: CONTACT, phone: 505-620-7815, email: anup.agarwal@medstar.net, geoPoint lat: 39.29038, lon: -76.61219, locations facility: Medstar Good Samaritan Hospital, status: RECRUITING, city: Baltimore, state: Maryland, zip: 21239, country: United States, contacts name: Sumanth Bandaru, MBBS, role: CONTACT, phone: 646-240-5289, email: sumanthkumar.bandaru@medstar.net, geoPoint lat: 39.29038, lon: -76.61219, hasResults: False
protocolSection identificationModule nctId: NCT06273072, orgStudyIdInfo id: IRB00409080, secondaryIdInfos id: R34HL166438-01A1, type: NIH, link: https://reporter.nih.gov/quickSearch/R34HL166438-01A1, briefTitle: Metformin IN Asthma for Overweight and Obese Individuals (MINA), statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05-01, primaryCompletionDateStruct date: 2026-09-30, completionDateStruct date: 2028-12-31, studyFirstPostDateStruct date: 2024-02-22, lastUpdatePostDateStruct date: 2024-03-15, sponsorCollaboratorsModule leadSponsor name: Johns Hopkins University, class: OTHER, collaborators name: Baylor College of Medicine, collaborators name: National Heart, Lung, and Blood Institute (NHLBI), collaborators name: Temple University, descriptionModule briefSummary: This is a randomized clinical trial of metformin among overweight or obese adults with not well-controlled asthma despite maintenance inhaler therapy., conditionsModule conditions: Asthma, conditions: Asthma Chronic, conditions: Overweight and Obesity, designModule studyType: INTERVENTIONAL, phases: PHASE2, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: QUADRUPLE, whoMasked: PARTICIPANT, whoMasked: CARE_PROVIDER, whoMasked: INVESTIGATOR, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 100, type: ESTIMATED, armsInterventionsModule interventions name: Metformin hydrochloride extended-release tablets, interventions name: Visually identical placebo Metformin hydrochloride extended-release tablets, outcomesModule primaryOutcomes measure: Number of completed telemedicine visits, primaryOutcomes measure: Adherence to study drug, primaryOutcomes measure: Retention rate, secondaryOutcomes measure: Asthma control as assessed by the Asthma Control Test (ACT) score, secondaryOutcomes measure: Change in Asthma exacerbations rate, secondaryOutcomes measure: Pre-bronchodilator lung function, secondaryOutcomes measure: Fractional exhaled nitric oxide (FeNO), secondaryOutcomes measure: Airways hyperresponsiveness, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06273059, orgStudyIdInfo id: 22-07-0717, briefTitle: Genomic Study of Young-Onset Diabetes Mellitus, statusModule overallStatus: RECRUITING, startDateStruct date: 2022-09-12, primaryCompletionDateStruct date: 2024-12-12, completionDateStruct date: 2024-12-12, studyFirstPostDateStruct date: 2024-02-22, lastUpdatePostDateStruct date: 2024-02-22, sponsorCollaboratorsModule leadSponsor name: Indonesia University, class: OTHER, descriptionModule briefSummary: Diabetes Mellitus (DM) has been a major contributor to health burden in Indonesia and currently its burden still continues to rise. This is a result of increasing DM prevalence in the country as well as high rates of chronic complications from DM. Findings in Indonesia show that there is a high proportion of young people with diabetes, and also a high risk of therapeutic failure and complications from DM occurring in the younger population.Young-onset DM has a wide clinical spectrum, including autoimmune DM, polygenic DM, and monogenic DM such as Mature Onset Diabetes of the Young (MODY). Identification and proper diagnosis of young-onset DM spectrum is crucial to treatment outcomes, as certain spectrums, such as some subtypes of MODY, may benefit from cost-efficient alternatives with better outcomes.However, proper diagnosis of young-onset DM in Indonesia is still a great challenge, as currently some examinations, including genetic testing, has not yet been feasibly done in the country. With current advances in genomics, genetic testing may prove to be fundamental in providing optimal and personalized treatment and care for DM patients.This study is a pilot project aimed to initiate genomic research in young-onset DM patients in Indonesia. In the short term, this study aims to identify genetic variants that may be able to increase diagnostic accuracy of the young-onset DM spectrum. In the long term, this study aims to identify new genetic variants of young-onset DM. The study also aims to identify genetic variants associated with risks of chronic complications., conditionsModule conditions: Genomic, conditions: Diabetes Mellitus, conditions: MODY, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: CROSS_SECTIONAL, enrollmentInfo count: 1000, type: ESTIMATED, armsInterventionsModule, outcomesModule primaryOutcomes measure: The overall objective of this study is to identify and describe genetic variation of young-onset DM in Indonesia., secondaryOutcomes measure: To describe the proportion of MODY in young-onset DM, secondaryOutcomes measure: To describe genetic variation of MODY in Indonesia., secondaryOutcomes measure: To describe genetic variation in young-onset DM with diabetic complications in various systems:, eligibilityModule sex: ALL, minimumAge: 8 Years, maximumAge: 40 Years, stdAges: CHILD, stdAges: ADULT, contactsLocationsModule locations facility: Cipto Mangunkusumo Hospital, status: RECRUITING, city: Jakarta Pusat, state: DKI Jakarta, zip: 10430, country: Indonesia, contacts role: CONTACT, phone: 1 500 135, geoPoint lat: -6.1818, lon: 106.8223, hasResults: False
protocolSection identificationModule nctId: NCT06273033, orgStudyIdInfo id: CONCORDE, briefTitle: Implementation of Contemporary Coronary CT Angiography in Clinical Practice, acronym: CONCORDE, statusModule overallStatus: RECRUITING, startDateStruct date: 2023-10-10, primaryCompletionDateStruct date: 2024-10, completionDateStruct date: 2025-01, studyFirstPostDateStruct date: 2024-02-22, lastUpdatePostDateStruct date: 2024-03-01, sponsorCollaboratorsModule leadSponsor name: Humanitas Hospital, Italy, class: OTHER, descriptionModule briefSummary: Coronary CT angiography (CCTA) has been recognized as the first-line diagnostic test for most patients with suspected coronary syndrome, often acting as a gatekeeper for invasive coronary angiography. It is therefore pivotal to understand instances of discrepancies that are encountered in clinical practice. Moreover, most of the literature on this topic relies on obsolete machines or definitions of coronary artery stenosis that cannot be defined as severe.The investigators aim 1) to report the real word data on the performance of last-generation CCTA in identifying obstructive coronary artery disease (also considering different thresholds of stenosis, i.e., moderate or severe) and 2) to identify predictors of discrepancies., conditionsModule conditions: Coronary Artery Disease of Significant Bypass Graft, conditions: Coronary Syndrome, conditions: Coronary Arteriosclerosis, designModule studyType: OBSERVATIONAL, designInfo observationalModel: OTHER, timePerspective: RETROSPECTIVE, enrollmentInfo count: 1000, type: ESTIMATED, armsInterventionsModule, outcomesModule primaryOutcomes measure: Diagnostic accuracy of CCTA for identifying coronary artery luminal stenosis ≥70% in a patient with suspected CAD., secondaryOutcomes measure: Diagnostic accuracy of CCTA for identifying coronary artery luminal stenosis ≥50% in a patient with suspected CAD., secondaryOutcomes measure: Diagnostic accuracy of CCTA for identifying coronary artery luminal stenosis ≥70% in a vessel of a patient with suspected CAD, secondaryOutcomes measure: Diagnostic accuracy of CCTA for identifying coronary artery luminal stenosis ≥50% in a vessel of a patient with suspected CAD, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: IRCCS Humanitas Research Hospital, status: RECRUITING, city: Rozzano, state: Milano, zip: 20089, country: Italy, contacts name: Carlo Andrea Pivato, MD, role: CONTACT, phone: +39 02 8224 7235, email: carlo.pivato@humanitas.it, geoPoint lat: 45.38193, lon: 9.1559, hasResults: False
protocolSection identificationModule nctId: NCT06273020, orgStudyIdInfo id: MI22-00013, briefTitle: Effect of Cerebrolysin on the Blood Brain Barrier in Patients With Diabetes and Ischemic Stroke, statusModule overallStatus: RECRUITING, startDateStruct date: 2022-11-17, primaryCompletionDateStruct date: 2024-11, completionDateStruct date: 2024-12, studyFirstPostDateStruct date: 2024-02-22, lastUpdatePostDateStruct date: 2024-02-22, sponsorCollaboratorsModule leadSponsor name: Hospital Universitario Dr. Jose E. Gonzalez, class: OTHER, collaborators name: Ever Neuro Pharma GmbH, descriptionModule briefSummary: A prospective, single-center study would be carried out in the Neurology Department of the University Hospital "Dr. José Eleuterio González" in order to analyze the effect of cerebrolysin on the blood-brain-barrier in patients with ischemic stroke with personal history of type-2 diabetes, conditionsModule conditions: Ischemic Stroke, Acute, conditions: Diabetes Mellitus, Type 2, conditions: Blood Brain Barrier, designModule studyType: INTERVENTIONAL, phases: PHASE4, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: There are 3 groups in this clinical trialGroup 1: 20 patients with previous intravenous thrombolysis (IVT) in the qualifying stroke and who agreed to receive and got selected (through randomization) cerebrolysin.Group 2 : 20 patients with previous IVT in the qualifying stroke and who agreed to receive cerebrolysin but they were not choose through randomization.Group 3: 20 patients that they were not candidates to receive IVT (out of therapeutic window) but agreed to receive cerebrolysin (randomization not used), primaryPurpose: SUPPORTIVE_CARE, maskingInfo masking: NONE, enrollmentInfo count: 60, type: ESTIMATED, armsInterventionsModule interventions name: Cerebrolysin, interventions name: Brain-MRI with contrast after 10-14 days of cerebrolysin, outcomesModule primaryOutcomes measure: Blood-Brain-Barrier Permeability after 10-14days of cerebrolysin in patients with AIS of the middle cerebral artery, secondaryOutcomes measure: Comparison of clinical severity, using NIH Stroke Scale in patients with and withouth cerebrolysin, secondaryOutcomes measure: Comparison of functional prognosis, using modified Rankin scale in patients with and withouth cerebrolysin, secondaryOutcomes measure: Comparison of cognitive impairment, using Montreal Cognitive Assessment in patients with and withouth cerebrolysin, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 80 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Servicio de Neurología del Hospital Universitario "Dr.José E. González", status: RECRUITING, city: Nuevo León, state: Monterrey, zip: 64020, country: Mexico, contacts name: Servicio F de Neurología del Hospital Universitario "Dr.José E. González", role: CONTACT, phone: +528183591111, email: neurologiahu.posgrado@gmail.com, contacts name: José C Becerra-Cruz, M.D., role: CONTACT, phone: +522324393970, email: becerracruz@hotmail.com, hasResults: False
protocolSection identificationModule nctId: NCT06272994, orgStudyIdInfo id: 231724, briefTitle: Swab Testing to Optimize Pneumonia Treatment With Empiric Vancomycin, acronym: STOP-Vanc, statusModule overallStatus: ENROLLING_BY_INVITATION, startDateStruct date: 2024-04-03, primaryCompletionDateStruct date: 2027-12-01, completionDateStruct date: 2027-12-31, studyFirstPostDateStruct date: 2024-02-22, lastUpdatePostDateStruct date: 2024-04-08, sponsorCollaboratorsModule leadSponsor name: Vanderbilt University Medical Center, class: OTHER, descriptionModule briefSummary: This is a single center, pragmatic, randomized clinical trial (pRCT) examining whether reporting the results of a negative rapid PCR back to the provider via a pager alert results in decreased vancomycin utilization for critically ill adults with community-acquired pneumonia when compared with usual care., conditionsModule conditions: Community-acquired Pneumonia, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: This study will be performed as a single center, pragmatic, randomized clinical trial., primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 212, type: ESTIMATED, armsInterventionsModule interventions name: MRSA Nasal Swab PCR, outcomesModule primaryOutcomes measure: Vancomycin-free hours alive, secondaryOutcomes measure: Time Alive off Vancomycin, secondaryOutcomes measure: 30-day all-cause mortality, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Vanderbilt University Medical Center, city: Nashville, state: Tennessee, zip: 37232, country: United States, geoPoint lat: 36.16589, lon: -86.78444, hasResults: False
protocolSection identificationModule nctId: NCT06272968, orgStudyIdInfo id: EA2/252/23, briefTitle: Predicting Cognition After DBS for Parkinson's Disease 2, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-02-25, primaryCompletionDateStruct date: 2027-12-01, completionDateStruct date: 2030-12-01, studyFirstPostDateStruct date: 2024-02-22, lastUpdatePostDateStruct date: 2024-02-22, sponsorCollaboratorsModule leadSponsor name: Charite University, Berlin, Germany, class: OTHER, descriptionModule briefSummary: The aim of the study is to improve estimation of cognitive outcome after STN-DBS in PD in order to avoid risk factors by optimizing peri- and intraoperative management personalize therapeutic strategies for optimal long-term benefit.The investigators will test possible predictors (clinical, neuropsychological, neuroimaging, electrophysiological and molecular) for the risk of cognitive dysfunction after deep brain stimulation of the subthalamic nucleus (STN-DBS) in Parkinson's disease (PD) at a single center (Charité - Universitätsmedizin Berlin, Germany). Data collection takes place prior to as well as 3, 12 and 60 months after the STN-DBS operation. Participation is proposed to all PD patients that are planned to undergo STN-DBS after careful examination of eligibility for this treatment according to standard operation procedures., conditionsModule conditions: Cognitive Impairment, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 30, type: ESTIMATED, armsInterventionsModule interventions name: Neuropsychological Testing, outcomesModule primaryOutcomes measure: Change in cognitive performance after STN-DBS, primaryOutcomes measure: Incidence of postoperative neurocognitive disorder, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 80 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Charité - Universitätsmedizin Berlin, city: Berlin, zip: 13351, country: Germany, geoPoint lat: 52.52437, lon: 13.41053, hasResults: False